Apresentação Pessoal

Curriculum vitae

1. Personal data

Cristina Maria Rodrigues Pinheiro Gavina (Cristina Gavina)

Birth place and date: Matosinhos (Portugal), 18-12-1973

Institutional address:

Department of Medicine, Faculty of Medicine, University of Porto

Rua Dr. Plácido da Costa, 4200-450 Porto, PORTUGAL

Tel: 351 22 5513644; Fax: 351 22 5513646

Email: cristina.gavina@gmail.com

  

2. Academic degrees 

Doctorate of Medicine (PhD), Faculty of Medicine of the University of Porto, Portugal, 2015

Medical Degree (MD), Faculty of Medicine of the University of Porto, Portugal, 1997

Postgraduate diploma (PGD) in Heath Management, Católica Oporto Business School, 2017

MSc in Clinical Trials student 21/22. Oxford University 

 

3. Clinical training

1998-99: General training, Hospital São João, Portugal

2000-2005: Specialist training in Cardiology, Hospital São João, Portugal

 

4. Previous and current clinical positions

Since Jun 2016- Director of Cardiology, Hospital Pedro Hispano, Unidade Local de Saúde de Matosinhos, Portugal

Since Feb 2016- Director of Department of Medicine, Hospital Pedro Hispano, Unidade Local de Saúde de Matosinhos, Portugal

Since 2020- Senior Consultant of Cardiology, Hospital Pedro Hispano, Unidade Local de Saúde de Matosinhos, Portugal

Since 2015- Consultant of Cardiology, Hospital Pedro Hispano, Unidade Local de Saúde de Matosinhos, Portugal

Since 2011 – Staff of Cardiology, Hospital Pedro Hispano, Unidade Local de Saúde de Matosinhos, Portugal

January 2007- March 2011- Head of the Intensive Cardiac Care Unit at Hospital de São João, Portugal

2005-2011 – Staff of Cardiology, Hospital São João, Porto, Portugal

2000-2005 – Resident in Cardiology, Hospital São João, Porto, Portugal

1998-1999 – Resident for General Training, Hospital São João, Porto, Portugal

 

5. Previous and current academic positions

Since 2019- Invited Assistant Professor of Medicine at the Faculty of Medicine of the University of Porto, PT

2007-2019 – Assistant of Medicine at the Faculty of Medicine of the University of Porto, PT

2009-2010 – Voluntary Assistant of Cardiology at the Faculty of Medicine of the University of Porto, PT

2002-2005 – Assistant of Physiology at the Faculty of Medicine, University of Porto, PT

 

6. Research interests

• Translational cardiovascular medicine; mechanisms underlying myocardial hypertrophy and progression to heart failure in aortic stenosis.
• Echocardiography in Valvular Heart Diseases.
• Heart Failure
• Cardiodiabetology
• Antithrombotic treatment in Acute Coronary Syndromes and Atrial Fibrillation.

 

7. Participation in Research Projects

2007: "Determinants of left ventricular hypertrophy before and after surgical treatment of aortic stenosis: clinical, morphofunctional, genetic and molecular correlations" (Ref.:POCI/SAU-PIC/IC/82943/2007)

2015: “NEw Targets in DIAstolic heart failure: from coMOrbidities to persoNalizeD medicine” (Ref: SAICTPAC/0047/2015)

2019: Cardiovascular Research and Development Center (Ref: UID/IC/00051/2019)

 

8. Awards and Honours

2018: Best classification in Post-graduation in Health Management 2017, Católica Oporto Business School

2016: Best Poster at Congresso Português de Cardiologia 2016, Portuguese Society of Cardiology

2012: Delta Prize in Arterial Hypertension, Portuguese Society of Cardiology.

2011: Sanofi-Aventis Prize in Cardiology, Portuguese Society of Cardiology.

2010: Delta Prize in Arterial Hypertension. Portuguese Society of Cardiology.

2010: Servier Prize in Heart Failure. Portuguese Society of Cardiology.

2008: João Porto Grant, Portuguese Society of Cardiology.

2007: Pfizer Investigation Scholarship. Sociedade das Ciências Médicas de Lisboa, Academia Portuguesa de Medicina/Pfizer Laboratories.

 

9. Scientific publications

Author or co-author in more than 70 publications resulting from meeting abstracts.

Author or co-author in 31 full text publications in peer-reviewed journals:

1. Prognostic Implications of Fibrosis in Low-Risk Aortic Stenosis Patients. Gavina C. et al. Rev Port Cardiol 2021 (accepted for publication)
2. Melo M, Gavina C, Silva-Nunes J, Andrade L, Carvalho D. Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?. Diabetol Metab Syndr. 2021;13(1):81. Published 2021 Jul 27. doi:10.1186/s13098-021-00698-5
3. Gavina C. Patient adherence to direct oral anticoagulants: To take or not to take, is it a patient's choice? Rev Port Cardiol (Engl Ed). 2021 Sep;40(9):677-678. doi: 10.1016/j.repce.2021.08.008
4. Os custos da aterosclerose em Portugal. Costa J et al. Rev Port Cardiol 2021 (in press)
5. MicroRNAs and Ventricular Remodeling in Aortic Stenosis. Gavina C, Faria J et al. Rev Port Cardiol. 2020;39(7):377-387.
6. Guia prático para a utilização dos inibidores da PCSK9 em Portugal. Fontes‐Carvalho, R., Silva, P. M., Rodrigues, E., Araújo, F., Gavina, C., Ferreira, J., & Morais, J. Rev Port Cardiol. 2019; 38(6): 391-405
7. Epidemiology of valvular heart disease in Portugal: The time has come for the heart valve unit. Gavina, C. Rev Port Cardiol. 2018 Dec 14. pii: S0870-2551(18)30790-X. doi: 10.1016/j.repc.2018.11.002
8. Comment on:“β‐Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction”. Gavina, C. Rev Port Cardiol. 2017; 36(10): 787-788
9. Is it time for sex-specific recommendations in aortic stenosis? Moura LM, Rocha-Gonçalves F, Gavina C. Heart 2017;103:1565-1566
10. Giant high-pressure pulmonary artery aneurysm in an elderly patient with chronic obstructive pulmonary disease. Morais S. A., Oliveira H. M., de Almeida J. R., Eiras E., Silva A. C., Gavina C. Rev Port Cardiol. 2016; 35(3): 183-e1.
11. Relevance of residual left ventricular hypertrophy after surgery for isolated aortic stenosis. Gavina C, Falcão-Pires I, Pinho P, Manso MC, Gonçalves A, Rocha-Gonçalves F, Leite-Moreira A. Eur J Cardiothorac Surg. 2015 Jul 18. pii: ezv240. [Epub ahead of print].
12. Recomendações da Sociedade Portuguesa de Cirurgia Cardio‐Torácica e Vascular e da Sociedade Portuguesa de Cardiologia sobre tempos de espera para cirurgia cardíaca. Neves J, Pereira H, Sousa Uva M, Gavina C, Leite Moreira A, Loureiro MJ. Rev Port Cardiol. 2015;34(11):683-689
13. Determinants of clinical improvement after surgical replacement or transcatheter aortic valve implantation for isolated aortic stenosis. Gavina C, Gonçalves A, Almeria C, Hernandez R, Leite-Moreira A, Rocha-Gonçalves F, Zamorano J. Cardiovasc Ultrasound. 2014 Oct 6;12:41.
14. Doença renal crónica em doentes com enfarte agudo do miocárdio sem elevação do segmento ST: niilismo terapêutico? MT Santos, RM Ferreira, C Rosario, L Carneiro, JM Costa, A Veloso, C Gavina. Portuguese Journal of Nephrology & Hypertension 2014;2 (1), 55-60
15. Establishment of heart teams in Portugal. M Sousa Uva, A Leite Moreira, C Gavina, H Pereira, MG Lopes. Rev Port Cardiol. 2014; 33 (1), 45-50
16. Load independent impairment of reverse remodeling after valve replacement in hypertensive aortic stenosis patients. C Gavina, I Falcão-Pires, J Rodrigues, B Marinho, N Gonçalves, R Lopes et al. International journal of cardiology 2014;170 (3), 324-330
17. Pseudoaneurisma gigante do ventrículo esquerdo: contributo diagnóstico de diferentes modalidades de imagem não invasivas.Oliveira SM, Dias P, Pinho T, Gavina C, Almeida PB, Madureira AJ, Pinho P, Ramos I, Maciel MJ. Rev Port Cardiol. 2012 Jun;31(6):439-44
18. Cardiac 123I-MIBG scintigraphy and arrhythmic risk in left ventricular noncompaction. Oliveira SM, Martins E, Oliveira A, Pinho T, Gavina C, Faria T, Silva-Cardoso JC, Pereira J, Maciel MJ. Rev Port Cardiol. 2012 Mar;31(3):247-50.
19. Understanding the Molecular and Cellular Changes Behind Aortic Valve Stenosis. I Falcao-Pires, C Gavina, A F Leite-Moreira. Current pharmaceutical biotechnology 2012; 13 (13), 2485-2496                 
20. Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle. C Gavina, I Falcao-Pires, F Rocha-Goncalves, A Leite-Moreira. Current pharmaceutical biotechnology 13 (13), 2012: 2503-2514
21. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. I Falcão-Pires, N Hamdani, A Borbély, C Gavina, CG Schalkwijk, et al. Circulation 2011; 124 (10), 1151-1159
22. Doença renal crônica e doença aterosclerótica cardiovascular: o risco cardiorenal. C Gavina. Rev Port Cardiol 2010;29 (Supl III), 19-25
23. Correlation between plasma levels of apelin and myocardial hypertrophy in rats and humans: possible target for treatment? I Falcão-Pires, N Gonçalves, C Gavina, S Pinho, T Teixeira, C Moura, et al. Expert opinion on therapeutic targets 2010; 14 (3), 231-241
24. Portuguese Registry of Acute Coronary Syndromes: seven years of activity. JF Santos, C Aguiar, C Gavina, P Azevedo, J Morais. Rev Port Cardiol 2009; 28, 1465-1500
25. The role of cardiovascular magnetic resonance in the evaluation of chest pain etiology: a case report. Oliveira SM, Pinho T, Gavina C, Madureira AJ, Rodrigues RA, Ramos I, Maciel MJ. Rev Port Cardiol. 2009 Sep;28(9):1005-14
26. Biomarkers in risk stratification of acute coronary syndromes: new insights into hematologic parameters. Gavina C. Rev Port Cardiol. 2009 Sep;28(9):925-7
27. Transient left ventricular ballooning syndrome. Silva C, Gonçalves A, Almeida R, Dias P, Araújo V, Gavina C, Maciel MJ. Eur J Intern Med. 2009 Sep;20(5):454-6
28. Complex ventricular septal rupture. The pivotal role of transesophageal echocardiography as support to surgery. Almeida J, Gavina C, Torres P, Pinho P. Rev Port Cardiol. 2009 Jan;28(1):105-10.
29. Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. A Borbély, I Falcao-Pires, L van Heerebeek, N Hamdani, I Édes, C Gavina, et al. Circulation Research 2009;104 (6), 780-786
30. Combined use of plasmapheresis and antidigoxin antibodies in a patient with severe digoxin intoxication and acute renal failure.Santos-Araújo C, Campos M, Gavina C, Rocha-Gonçalves F, Pestana M. Nephrol Dial Transplant. 2007 Jan;22(1):257-8
31. The value of NT-proBNP in early risk stratification of acute coronary syndromes. Almeida R, Mariano L, Gavina C, Pinho T, Vasconcelos M, Ferreira A, Maciel MJ, Gonçalves FR. Rev Port Cardiol. 2006 Jan;25(1):71-5.

 

10. Other relevant activities                                                                                                 

• Member of the Working Group for the Treatment of Heart Failure in Portugal (Portuguese Ministry of Health, Act nº 4583/2018. Diário da República n.º 90/2018, Série II of 2018-05-10)
• Member of the Cardiovascular Research and Development Unit (UnIC) of the Medical School of Oporto University
• Direction of scientific societies:
  • Vice President of the Portuguese Society of Cardiology 2019-2021;
  • Member of the Board of the Portuguese Society of Cardiology 2017-2019;
  • Director of the Cardiovascular Academy of the Portuguese Society of Cardiology 2017-2021
  • National Director of Training of the European Society of Cardiology 2017-2021;
  • Member of the Scientific Council of the Portuguese Society of Atherosclerosis 2017-2020;
  • Member of the Working Group of Platelets and Thrombosis of the Portuguese Society of Cardiology from 2015-2017;
  • Member of the Working Group of Valvular Heart Diseases of the Portuguese Society of Cardiology from 2011-2015;
  • Member of the Working Group of Intensive Care in Cardiology of the Portuguese Society of Cardiology from 2007-2011.
• Coordinator of the Clinical Trials Center and Head of the Service for Investigation and Resources Management at the Unidade Local de Saúde de Matosinhos (ULSM), Portugal, from 2013-2016
• Editorial Board of the Portuguese Journal of Cardiology, from 2016 to present
• Certification in Good Clinical Practice (valid until 23 April 2022)
• Experience in clinical trials:
  • Principal Investigator in the ongoing multicenter clinical trial Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)
  • Principal Investigator in the ongoing multicenter clinical trial Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II).
  • Principal Investigator in the ongoing multicenter clinical trial A multicentre, randomised, open-label, parallel-group trial to study the safety and non-inferiority of a new therapeutic strategy (the Fuster-CNIC-Ferrer cardiovascular polypill) versus usual care on LDLc and blood pressure reduction in patients with atherothrombotic cardiovascular disease: The APOLO trial.
  • Principal Investigator in the ongoing multicenter clinical trial Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS (dal-GenE), a placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile randomized to dalcetrapib vs placebo.
  • Principal Investigator in multicenter clinical trial A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER HF), a phase III double blind randomized trial comparing anticoagulation with low-dose rivaroxaban vs placebo in heart failure patients in sinus rhythm.
  • Principal Investigator in multicenter clinical trial Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes (TRACER), a phase III double blind randomized trial comparing antiagregation with vorapaxar vs placebo in acute coronary syndromes (ACS).
  • Principal Investigator in multicenter clinical trial Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes(IMPROVE-IT), a phase III double blind randomized trial comparing cholesterol lowering with simvastatin/ezetimibe vs simvastatin in ACS.
  • National Coordinator of the multicenter observational study Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients (TIGRIS).

 

26 September 2021